References

evrazkar

Евразийский Кардиологический Журнал

Eurasian heart journal

2225-16852305-0748

Евразийская ассоциация кардиологов

10.38109/2225-1685-2020-2-6-29

evrazkar-6203

Research Article

КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ

CLINICAL GUIDELINES

КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ ЕВРАЗИЙСКОЙ АССОЦИАЦИИ КАРДИОЛОГОВ (ЕАК)/ НАЦИОНАЛЬНОГО ОБЩЕСТВА ПО ИЗУЧЕНИЮ АТЕРОСКЛЕРОЗА (НОА, РОССИЯ) ПО ДИАГНОСТИКЕ И КОРРЕКЦИИ НАРУШЕНИЙ ЛИПИДНОГО ОБМЕНА С ЦЕЛЬЮ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ АТЕРОСКЛЕРОЗА (2020)

EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ RUSSIAN NATIONAL ATHEROSCLEROSIS SOCIETY (RNAS, RUSSIA) GUIDELINES FOR THE DIAGNOSIS AND CORRECTION OF DYSLIPIDEMIA FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS (2020)

Кухарчук

В. В.

Kukharchuk

V. V.

Рабочая группа

Valery V. Kukharchuk

Working group

https://orcid.org/0000-0002-1518-6552

Ежов

М. В.

Ezhov

M. V.

Марат Владиславович Ежов, д.м.н., профессор, главный научный сотрудник, отдел проблем атеросклероза, институт клинической кардиологии им. А.Л. Мясникова

121552, Москва, ул. 3-я Черепковская, д. 15а

телефон/факс: +7-495-414-6067

Рабочая группа

Marat V. Ezhov MD, PhD, DMSc, Main Researcher, Head of Laboratory of Lipid Disorders

3rd Cherepkovskaya street, 15a, Moscow 121552

Phone/Fax:+7-495-414-6067

Working group

marat_ezhov@mail.ru

Сергиенко

И. В.

Sergienko

I. V.

Рабочая группа

Igor V. Sergienko

Working group

Арабидзе

Г. Г.

Arabidze

G. G.

Рабочая группа

Grigory G. Arabidze

Working group

Балахонова

Т. В.

Balakhonova

T. V.

Рабочая группа

Tatyana V. Balakhonova

Working group

Гуревич

В. С.

Gurevich

V. S.

Рабочая группа

Victor S. Gurevich

Working group

Зелвеян

П. А.

Zelveyan

P. A.

Рабочая группа

Parunak A. Zelveyan

Working group

Мураталиев

Т. М.

Murataliev

T. M.

Рабочая группа

Tulkun M. Murataliev

Working group

Мырзахметова

Г. Ш.

Myrzakhmetova

G. Sh.

Рабочая группа

Gulzhan Sh. Myrzakhmetova

Working group

Суджаева

О. А.

Sudzhaeva

O. A.

Рабочая группа

Olga A. Sudzhaeva

Working group

Шек

А. Б.

Shek

A. B.

Рабочая группа

Alexander B. Shek

Working group

Азизов

В. А.

Azizov

V. A.

Рабочая группа

Vasadat A. Azizov

Working group

Горнякова

Н. Б.

Gornyakova

N. B.

Рабочая группа

Natalya B. Gornyakova

Working group

Качковский

М. А.

Kachkovsky

M. A.

Рабочая группа

Michael A. Kachkovsky

Working group

Малышев

П. П.

Malyshev

P. P.

Рабочая группа

Pavel P. Malyshev

Working group

Покровский

С. Н.

Pokrovsky

S. N.

Рабочая группа

Sergei N. Pokrovsky

Working group

Соколов

А. А.

Sokolov

A. A.

Рабочая группа

Alexey A. Sokolov

Working group

Сумароков

А. Б.

Sumarokov

A. B.

Рабочая группа

Alexander B. Sumarokov

Working group

Обрезан

А. Г.

Obrezan

A. G.

Рабочая группа

Andrei G. Obrezan

Working group

Шапошник

И. И.

Shaposhnik

I. I.

Рабочая группа

Igor I. Shaposhnik

Working group

Анциферов

М. Б.

Antsiferov

M. B.

Соавторы рекомендаций

Michael B. Antsiferov

Co-authors of the guidelines

Аншелес

А. А.

Ansheles

A. A.

Соавторы рекомендаций

Alexey A. Ansheles

Co-authors of the guidelines

Аронов

Д. М.

Aronov

D. M.

Соавторы рекомендаций

David M. Aronov

Co-authors of the guidelines

Ахмеджанов

Н. М.

Akhmedzhanov

N. M.

Соавторы рекомендаций

Nadir M. Akhmedzhanov

Co-authors of the guidelines

Барбараш

О. Л.

Barbarash

O. L.

Соавторы рекомендаций

Ol’ga L. Barbarash

Co-authors of the guidelines

Бойцов

С. А.

Boytsov

S. A.

Соавторы рекомендаций

Sergei A. Boytsov

Co-authors of the guidelines

Бубнова

М. Г.

Bubnova

M. G.

Соавторы рекомендаций

Marina G. Bubnova

Co-authors of the guidelines

Воевода

М. И.

Voevoda

M. I.

Соавторы рекомендаций

Michael I. Voevoda

Co-authors of the guidelines

Галстян

Г. Р.

Galstyan

G. R.

Соавторы рекомендаций

Gagik R. Galstyan

Co-authors of the guidelines

Галявич

А. С.

Galyavich

A. S.

Соавторы рекомендаций

Albert S. Galyavich

Co-authors of the guidelines

Драпкина

О. М.

Drapkina

O. M.

Соавторы рекомендаций

Oksana M. Drapkina

Co-authors of the guidelines

Дупляков

Д. В.

Duplyakov

D. V.

Соавторы рекомендаций

Dmitrij V. Duplyakov

Co-authors of the guidelines

Ерёгин

С. Я.

Eregin

S. Ya.

Соавторы рекомендаций

Sergei Ya. Eregin

Co-authors of the guidelines

Карпов

Р. С.

Karpov

R. S.

Соавторы рекомендаций

Rostislav S. Karpov

Co-authors of the guidelines

Карпов

Ю. А.

Karpov

Yu. A.

Соавторы рекомендаций

Yurij A. Karpov

Co-authors of the guidelines

Козиолова

Н. А.

Koziolova

N. A.

Соавторы рекомендаций

Natal’ya A. Koziolova

Co-authors of the guidelines

Коновалов

Г. А.

Konovalov

G. A.

Соавторы рекомендаций

Gennadij A. Konovalov

Co-authors of the guidelines

Константинов

В. О.

Konstantinov

V. O.

Соавторы рекомендаций

Vladimir O. Konstantinov

Co-authors of the guidelines

Космачёва

Е. Д.

Kosmacheva

E. D.

Соавторы рекомендаций

Elena D. Kosmacheva

Co-authors of the guidelines

Недогода

С. В.

Nedogoda

S. V.

Соавторы рекомендаций

Sergej V. Nedogoda

Co-authors of the guidelines

Олейников

В. Э.

Olejnikov

V. E.

Соавторы рекомендаций

Valentin E. Olejnikov

Co-authors of the guidelines

Рагино

Ю. И.

Ragino

Yu. I.

Соавторы рекомендаций

Yuliya I. Ragino

Co-authors of the guidelines

Скибицкий

В. В.

Skibickij

V. V.

Соавторы рекомендаций

Vitalij V. Skibickij

Co-authors of the guidelines

Смоленская

О. Г.

Smolenskaya

O. G.

Соавторы рекомендаций

Ol’ga G. Smolenskaya

Co-authors of the guidelines

Халимов

Ю. Ш.

Halimov

Yu. Sh.

Соавторы рекомендаций

Yurij Sh. Halimov

Co-authors of the guidelines

Чазова

И. Е.

Chazova

I. E.

Соавторы рекомендаций

Irina E. Chazova

Co-authors of the guidelines

Филиппов

А. Е.

Filippov

A. E.

Соавторы рекомендаций

Aleksandr E. Filippov

Co-authors of the guidelines

Шестакова

М. В.

Shestakova

M. V.

Соавторы рекомендаций

Marina V. Shestakova

Co-authors of the guidelines

Якушин

С. С.

Yakushin

S. S.

Соавторы рекомендаций

Sergei S. Yakushin

Co-authors of the guidelines

ФГБУ «НМИЦК» Минздрава РФРоссияNational Medical Research Center of CardiologyRussian Federation

2020

30062020

02629

Copyright © Кухарчук В.В., Ежов М.В., Сергиенко И.В., Арабидзе Г.Г., Балахонова Т.В., Гуревич В.С., Зелвеян П.А., Мураталиев Т.М., Мырзахметова Г.Ш., Суджаева О.А., Шек А.Б., Азизов В.А., Горнякова Н.Б., Качковский М.А., Малышев П.П., Покровский С.Н., Соколов А.А., Сумароков А.Б., Обрезан А.Г., Шапошник И.И., Анциферов М.Б., Аншелес А.А., Аронов Д.М., Ахмеджанов Н.М., Барбараш О.Л., Бойцов С.А., Бубнова М.Г., Воевода М.И., Галстян Г.Р., Галявич А.С., Драпкина О.М., Дупляков Д.В., Ерёгин С.Я., Карпов Р.С., Карпов Ю.А., Козиолова Н.А., Коновалов Г.А., Константинов В.О., Космачёва Е.Д., Недогода С.В., Олейников В.Э., Рагино Ю.И., Скибицкий В.В., Смоленская О.Г., Халимов Ю.Ш., Чазова И.Е., Филиппов А.Е., Шестакова М.В., Якушин С.С., 2020

2020

Кухарчук В.В., Ежов М.В., Сергиенко И.В., Арабидзе Г.Г., Балахонова Т.В., Гуревич В.С., Зелвеян П.А., Мураталиев Т.М., Мырзахметова Г.Ш., Суджаева О.А., Шек А.Б., Азизов В.А., Горнякова Н.Б., Качковский М.А., Малышев П.П., Покровский С.Н., Соколов А.А., Сумароков А.Б., Обрезан А.Г., Шапошник И.И., Анциферов М.Б., Аншелес А.А., Аронов Д.М., Ахмеджанов Н.М., Барбараш О.Л., Бойцов С.А., Бубнова М.Г., Воевода М.И., Галстян Г.Р., Галявич А.С., Драпкина О.М., Дупляков Д.В., Ерёгин С.Я., Карпов Р.С., Карпов Ю.А., Козиолова Н.А., Коновалов Г.А., Константинов В.О., Космачёва Е.Д., Недогода С.В., Олейников В.Э., Рагино Ю.И., Скибицкий В.В., Смоленская О.Г., Халимов Ю.Ш., Чазова И.Е., Филиппов А.Е., Шестакова М.В., Якушин С.С.

Kukharchuk V.V., Ezhov M.V., Sergienko I.V., Arabidze G.G., Balakhonova T.V., Gurevich V.S., Zelveyan P.A., Murataliev T.M., Myrzakhmetova G.S., Sudzhaeva O.A., Shek A.B., Azizov V.A., Gornyakova N.B., Kachkovsky M.A., Malyshev P.P., Pokrovsky S.N., Sokolov A.A., Sumarokov A.B., Obrezan A.G., Shaposhnik I.I., Antsiferov M.B., Ansheles A.A., Aronov D.M., Akhmedzhanov N.M., Barbarash O.L., Boytsov S.A., Bubnova M.G., Voevoda M.I., Galstyan G.R., Galyavich A.S., Drapkina O.M., Duplyakov D.V., Eregin S.Y., Karpov R.S., Karpov Y.A., Koziolova N.A., Konovalov G.A., Konstantinov V.O., Kosmacheva E.D., Nedogoda S.V., Olejnikov V.E., Ragino Y.I., Skibickij V.V., Smolenskaya O.G., Halimov Y.S., Chazova I.E., Filippov A.E., Shestakova M.V., Yakushin S.S.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.heartj.asia/jour/article/view/6203

Отказ от ответственности. Рекомендации ЕАК/НОА отражают точку зрения ЕАК и НОА и были подготовлены после тщательного изучения научных и медицинских данных, имеющихся на момент их публикации. ЕАК и НОА не несут ответственности в случае какого-либо противоречия, несоответствия и / или неоднозначности между Рекомендациями ЕАК/НОА и любыми другими официальными рекомендациями или руководствами, выпущенными соответствующими органами общественного здравоохранения, в частности, в отношении правильного использования медицинских или терапевтических стратегий. Медицинским работникам рекомендуется в полной мере учитывать Рекомендации ЕАК/НОА при оценке своего клинического суждения, а также при определении и реализации профилактических, диагностических или терапевтических медицинских стратегий. Тем не менее Рекомендации ЕАК/НОА никоим образом не отменяют индивидуальную ответственность медицинских работников за принятие надлежащих и точных решений с учетом состояния здоровья каждого пациента и в консультации с этим пациентом и, при необходимости и / или необходимости, опекуна пациента. Рекомендации ЕАК/НОА не освобождают медицинских работников от полного и тщательного рассмотрения соответствующих официальных обновленных рекомендаций или руководств, выпущенных компетентными органами общественного здравоохранения, для рассмотрения каждого медицинского случая в свете современных научно обоснованных рекомендаций в соответствии с их этическими и профессиональными обязательствами. Кроме того, медицинский работник обязан проверять действующие правила и положения, касающиеся лекарств и медицинских изделий, на момент назначения по рецепту.

Члены Рабочей группы подтвердили отсутствие финансовой поддержки/ конфликта интересов. В случае сообщения о наличии конфликта интересов член(ы) Рабочей группы был(и) исключен(ы) из обсуждения разделов, связанных с областью конфликта интересов.

Disclaimer РThe EAC/RNAS Guidelines represent the views of the EAC and RNAS, and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The EAC and RNAS is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the EAC/RNAS Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the EAC/RNAS Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the EAC/RNAS Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the EAC/RNAS Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

Members of the Working Group confirmed the lack of financial support / conflict of interest. In the event of a conflict of interest being reported, the member (s) of the Working Group was (were) excluded from the discussion of sections related to the area of conflict of interest.

дислипидемияатеросклерозхолестеринтриглицеридыгиполипидемическая терапия

dyslipidemiaatherosclerosischolesteroltriglycerideslipidlowering therapy

References1

Стратегия развития здравоохранения в Российской Федерации на период до 2025 года. Указ президента Российской Федерации от 06 июня 2019 г. №254. Москва, 2019.

Healthcare development strategy in the Russian Federation for the period until 2025. Presidential Decree of the Russian Federation of June 6, 2019 No. 254. Moscow, 2019 (in Russ.).

Россия в цифрах 2019. Краткий статистический сборник. М.: Росстат. 2019.

Russia in numbers 2019. A brief statistical compilation. M.: Rosstat. 2019 (in Russ.).

Ежов М.В., Сергиенко И.В., Аронов Д.М., et al. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Атеросклероз и дислипидемии. 2017. Т. 3. С. 5-22.

Ezhov M.V., Sergienko I.V., D.M. Aronov et al. Diagnostics and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Atherosclerosis and dyslipidemia. 2017. (3):5-22 (in Russ.).

Piepoli M.F., Hoes A.W., Agewall S., et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016. 37(29): 2315-2381. doi: 10.1093/eurheartj/ehw106

Mach F., Baigent C., Catapano A.L., et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019. doi: 10.1093/eurheartj/ehz455

Langsted A., Nordestgaard B.G. Nonfasting versus fasting lipid profile for cardiovascular risk prediction. Pathology. 2019. 51(2): 131-141. doi: 10.1016/j.pathol.2018.09.062

Farukhi Z., Mora S. The Future of Low-Density Lipoprotein Cholesterol in an Era of Nonfasting Lipid Testing and Potent Low-Density Lipoprotein Lowering. Circulation. 2018. 137(1): 20-23. doi: 10.1161/CIRCULATIONAHA.117.031857

Langsted A., Nordestgaard B.G. Nonfasting Lipids, Lipoproteins, and Apolipoproteins in Individuals with and without Diabetes: 58 434 Individuals from the Copenhagen General Population Study. Clin Chem. 2010. 57(3): 482-489. doi: 10.1373/clinchem.2010.157164

Meijboom W.B., Meijs M.F., Schuijf J.D., et al. Diagnostic accuracy of 64-slice computed tomography coronary angiography: a prospective, multicenter, multivendor study. J Am Coll Cardiol. 2008. 52(25): 2135- 2144. doi: 10.1016/j.jacc.2008.08.058

Agatston A.S., Janowitz W.R., Hildner F.J., et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990. 15(4): 827-832. doi: 10.1016/0735-1097(90)90282-t

Serrano C.V., de Mattos F.R., Pitta F.G., et al. Association between Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios and Coronary Artery Calcification Score among Asymptomatic Patients: Data from a Cross-Sectional Study. Mediators Inflamm. 2019. 2019: 1-8. doi: 10.1155/2019/6513847

Perk J., De Backer G., Gohlke H., et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Atherosclerosis. 2012. 223(1): 1-68. doi: 10.1016/j.atherosclerosis.2012.05.007

Mortensen M.B., Falk E., Li D., et al. Statin Trials, Cardiovascular Events, and Coronary Artery Calcification. JACC: Cardiovascular Imaging. 2018. 11(2): 221-230. doi: 10.1016/j.jcmg.2017.01.029

McDermott M.M., Kramer C.M., Tian L., et al. Plaque Composition in the Proximal Superficial Femoral Artery and Peripheral Artery Disease Events. JACC: Cardiovascular Imaging. 2017. 10(9): 1003-1012. doi: 10.1016/j.jcmg.2016.08.012

Sillesen H., Sartori S., Sandholt B., et al. Carotid plaque thickness and carotid plaque burden predict future cardiovascular events in asymptomatic adult Americans. European Heart Journal - Cardiovascular Imaging. 2017. 19(9): 1042-1050. doi: 10.1093/ehjci/jex239

Perrone-Filardi P., Achenbach S., Mohlenkamp S., et al. Cardiac computed tomography and myocardial perfusion scintigraphy for risk stratification in asymptomatic individuals without known cardiovascular disease: a position statement of the Working Group on Nuclear Cardiology and Cardiac CT of the European Society of Cardiology. Eur Heart J. 2010. 32(16): 1986-1993. doi: 10.1093/eurheartj/ehq235

Den Ruijter H.M., Peters S.A.E., Anderson T.J., et al. Common Carotid Intima-Media Thickness Measurements in Cardiovascular Risk Prediction. JAMA. 2012. 308(8): 796-803. doi: 10.1001/jama.2012.9630

Stein J.H., Korcarz C.E., Hurst R.T., et al. Use of Carotid Ultrasound to Identify Subclinical Vascular Disease and Evaluate Cardiovascular Disease Risk: A Consensus Statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force Endorsed by the Society for Vascular Medicine. Journal of the American Society of Echocardiography. 2008. 21(2): 93-111. doi: 10.1016/j.echo.2007.11.011

Vlachopoulos C., Xaplanteris P., Aboyans V., et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation. Atherosclerosis. 2015. 241(2): 507-532. doi: 10.1016/j.atherosclerosis.2015.05.007

Robinson J.G., Williams K.J., Gidding S., et al. Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life. J Am Heart Assoc. 2018. 7(20). doi: 10.1161/jaha.118.009778

Kamstrup P.R. Lipoprotein(a): the common, likely causal, yet elusive risk factor for cardiovascular disease. J Lipid Res. 2017. 58(9): 1731-1732. doi: 10.1194/jlr.c079111

Tsimikas S., Fazio S., Ferdinand K.C., et al. NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. J Am Coll Cardiol. 2018. 71(2): 177-192. doi: 10.1016/j.jacc.2017.11.014

Eckel R.H., Jakicic J.M., Ard J.D., et al. 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk. Circulation. 2013. 129(25 suppl 2): S76-S99. doi: 10.1161/01.cir.0000437740.48606.d1

de Lorgeril M., Salen P., Martin J.-L., et al. Mediterranean Diet, Traditional Risk Factors, and the Rate of Cardiovascular Complications After Myocardial Infarction. Circulation. 1999. 99(6): 779-785. doi: 10.1161/01.cir.99.6.779

Estruch R., Ros E., Salas-Salvado J., et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med. 2018. 378(25): e34. doi: 10.1056/NEJMoa1800389

Mozaffarian D., Lemaitre R.N., King I.B., et al. Plasma Phospholipid LongChain ω-3 Fatty Acids and Total and Cause-Specific Mortality in Older Adults. Ann Intern Med. 2013. 158(7): 515-525. doi: 10.7326/0003- 4819-158-7-201304020-00003

Lu Z., Kou W., Du B., et al. Effect of Xuezhikang, an Extract From Red Yeast Chinese Rice, on Coronary Events in a Chinese Population With Previous Myocardial Infarction. Am J Cardiol. 2008. 101(12): 1689- 1693. doi: 10.1016/j.amjcard.2008.02.056

Li Y., Jiang L., Jia Z., et al. A Meta-Analysis of Red Yeast Rice: An Effective and Relatively Safe Alternative Approach for Dyslipidemia. PLoS One. 2014. 9(6): e98611. doi: 10.1371/journal.pone.0098611

Taylor F., Huffman M.D., Macedo A.F., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. 2013. doi: 10.1002/14651858.cd004816.pub5

Sever P.S., Dahlöf B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the AngloScandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOTLLA): a multicentre randomised controlled trial. The Lancet. 2003. 361(9364): 1149-1158. doi: 10.1016/s0140-6736(03)12948-0

Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. The Lancet. 2004. 364(9435): 685- 696. doi: 10.1016/s0140-6736(04)16895-5

Schwartz G.G. Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary SyndromesThe MIRACL Study: A Randomized Controlled Trial. JAMA. 2001. 285(13): 1711. doi: 10.1001/jama.285.13.1711

Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004. 350(15): 1495-1504. doi: 10.1056/NEJMoa040583

Patti G., Pasceri V., Colonna G., et al. Atorvastatin Pretreatment Improves Outcomes in Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention. J Am Coll Cardiol. 2007. 49(12): 1272-1278. doi: 10.1016/j.jacc.2007.02.025

Shepherd J., Kastelein J.J., Bittner V., et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008. 51(15): 1448-1454. doi: 10.1016/j.jacc.2007.11.072

Athyros V.G., Papageorgiou A.A., Mercouris B.R., et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin. 2002. 18(4): 220-228. doi: 10.1185/030079902125000787

Amarenco P., Bogousslavsky J., Callahan A., 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006. 355(6): 549-559. doi: 10.1056/NEJMoa061894

Newman C.B., Palmer G., Silbershatz H., et al. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol. 2003. 92(6): 670-676. doi: 10.1016/s0002-9149(03)00820-8

Group S.C. Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J. 2010. 160(5): 785-794.e710. doi: 10.1016/j.ahj.2010.08.012

Abifadel M., Varret M., Rabès J.-P., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003. 34(2): 154-156. doi: 10.1038/ng1161

Norata G.D., Tibolla G., Catapano A.L. Targeting PCSK9 for Hypercholesterolemia. Annual Review of Pharmacology and Toxicology. 2014. 54(1): 273-293. doi: 10.1146/annurev-pharmtox-011613-140025

Cannon C.P., Blazing M.A., Giugliano R.P., et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015. 372(25): 2387-2397. doi: 10.1056/NEJMoa1410489

Sabatine M.S., Giugliano R.P., Keech A.C., et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine. 2017. 376(18): 1713-1722. doi: 10.1056/nejmoa1615664

Giugliano R.P., Pedersen T.R., Park J.-G., et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. The Lancet. 2017. 390(10106): 1962-1971. doi: 10.1016/s0140-6736(17)32290-0

Boekholdt S.M., Hovingh G.K., Mora S., et al. Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events. J Am Coll Cardiol. 2014. 64(5): 485-494. doi: 10.1016/j.jacc.2014.02.615

Schwartz G.G., Steg P.G., Szarek M., et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018. 379(22): 2097-2107. doi: 10.1056/NEJMoa1801174

Castelli W.P. Epidemiology of triglycerides: A view from Framingham. Am J Cardiol. 1992. 70(19): H3-H9. doi: 10.1016/0002-9149(92)91083-g

Barter P., Gotto A.M., LaRosa J.C., et al. HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events. New England Journal of Medicine. 2007. 357(13): 1301-1310. doi: 10.1056/nejmoa064278

Carey V.J., Bishop L., Laranjo N., et al. Contribution of High Plasma Triglycerides and Low High-Density Lipoprotein Cholesterol to Residual Risk of Coronary Heart Disease After Establishment of Low-Density Lipoprotein Cholesterol Control. Am J Cardiol. 2010. 106(6): 757-763. doi: 10.1016/j.amjcard.2010.05.002

Aguiar C., Alegria E., Bonadonna R.C., et al. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate– statin combination therapy. Atherosclerosis Supplements. 2015. 19: 1-12. doi: 10.1016/s1567-5688(15)30001-5

National Cholesterol Education Program Expert Panel on Detection E., Treatment of High Blood Cholesterol in A. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002. 106(25): 3143-3421. doi:

Hegele R.A., Ginsberg H.N., Chapman M.J., et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014. 2(8): 655-666. doi: 10.1016/S2213-8587(13)70191-8

Ghandehari H., Kamal-Bahl S., Wong N.D. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: The National Health and Nutrition Examination Survey 2003-2004. Am Heart J. 2008. 156(1): 112-119. doi: 10.1016/j.ahj.2008.03.005

Gitt A.K., Drexel H., Feely J., et al. Persistent lipid abnormalities in statintreated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prev Cardiol. 2011. 19(2): 221-230. doi: 10.1177/1741826711400545

Yuan G., Al-Shali K.Z., Hegele R.A. Hypertriglyceridemia: its etiology, effects and treatment. Can Med Assoc J. 2007. 176(8): 1113-1120. doi: 10.1503/cmaj.060963

Reaven G.M., Chen Y.D., Jeppesen J., et al. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. Journal of Clinical Investigation. 1993. 92(1): 141-146. doi: 10.1172/jci116541

Ridker P.M., Rifai N., Cook N.R., et al. Non–HDL Cholesterol, Apolipoproteins A-I and B100, Standard Lipid Measures, Lipid Ratios, and CRP as Risk Factors for Cardiovascular Disease in Women. JAMA. 2005. 294(3): 326. doi: 10.1001/jama.294.3.326

Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. New England Journal of Medicine. 2010. 362(17): 1563-1574. doi: 10.1056/nejmoa1001282

Bhatt D.L., Steg P.G., Miller M., et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New England Journal of Medicine. 2019. 380(1): 11-22. doi: 10.1056/nejmoa1812792

Fruchart J.C., Duriez P. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs of Today. 2006. 42(1): 39. doi: 10.1358/dot.2006.42.1.963528

Keating G.M., Croom K.F. Fenofibrate. Drugs. 2007. 67(1): 121-153. doi: 10.2165/00003495-200767010-00013

Cholesterol Treatment Trialists C., Baigent C., Blackwell L., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010. 376(9753): 1670-1681. doi: 10.1016/S0140-6736(10)61350-5

Mark L., Dani G., Fazekas Ö., et al. Effects of ezetimibe on lipids and lipoproteins in patients with hypercholesterolemia and different apolipoprotein E genotypes. Curr Med Res Opin. 2007. 23(7): 1541- 1548. doi: 10.1185/030079907x199817

Kim N.H., Han K.H., Choi J., et al. Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study. BMJ. 2019. 366: l5125. doi: 10.1136/bmj.l5125

Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. The Lancet. 2001. 357(9260): 905-910. doi: 10.1016/s0140-6736(00)04209-4

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. The Lancet. 2005. 366(9500): 1849-1861. doi: 10.1016/s0140-6736(05)67667-2

Kovacs C.S., Seshiah V., Swallow R., et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes, Obesity and Metabolism. 2013. 16(2): 147-158. doi: 10.1111/dom.12188

Zinman B., Wanner C., Lachin J.M., et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2015. 373(22): 2117-2128. doi: 10.1056/nejmoa1504720

Marso S.P., Daniels G.H., Brown-Frandsen K., et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2016. 375(4): 311-322. doi: 10.1056/nejmoa1603827

Marso S.P., Bain S.C., Consoli A., et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016. 375(19): 1834-1844. doi: 10.1056/NEJMoa1607141

Cosentino F., Grant P.J., Aboyans V., et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019. doi: 10.1093/eurheartj/ehz486

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet. 1998. 352(9131): 854-865. doi: 10.1016/s0140-6736(98)07037-8

Nordestgaard B.G., Chapman M.J., Humphries S.E., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013. 34(45): 3478-3490a. doi: 10.1093/eurheartj/eht273

Rosengren A. Better treatment and improved prognosis in elderly patients with AMI: but do registers tell the whole truth? Eur Heart J. 2012. 33(5): 562-563. doi: 10.1093/eurheartj/ehr364

Prospective Studies C., Lewington S., Whitlock G., et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007. 370(9602): 1829-1839. doi: 10.1016/S0140-6736(07)61778-4

Second Joint Task Force of E. Prevention of coronary heart disease in clinical practice Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J. 1998. 19(10): 1434-1503. doi: 10.1053/euhj.1998.1243

Lloyd-Jones D.M., Leip E.P., Larson M.G., et al. Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age. Circulation. 2006. 113(6): 791-798. doi: 10.1161/circulationaha.105.548206

Berry J.D., Dyer A., Cai X., et al. Lifetime Risks of Cardiovascular Disease. New England Journal of Medicine. 2012. 366(4): 321-329. doi: 10.1056/nejmoa1012848

Giang K.W., Björck L., Novak M., et al. Stroke and coronary heart disease: predictive power of standard risk factors into old age—longterm cumulative risk study among men in Gothenburg, Sweden. Eur Heart J. 2013. 34(14): 1068-1074. doi: 10.1093/eurheartj/ehs458

Wilhelmsen L., Svärdsudd K., Eriksson H., et al. Factors associated with reaching 90 years of age: a study of men born in 1913 in Gothenburg, Sweden. J Intern Med. 2010. 269(4): 441-451. doi: 10.1111/j.1365-2796.2010.02331.x

Reiner Ž. Primary Prevention of Cardiovascular Disease with Statins in the Elderly. Curr Atheroscler Rep. 2014. 16(7). doi: 10.1007/s11883-014-0420-6

Savarese G., Gotto A.M., Paolillo S., et al. Benefits of Statins in Elderly Subjects Without Established Cardiovascular Disease. J Am Coll Cardiol. 2013. 62(22): 2090-2099. doi: 10.1016/j.jacc.2013.07.069

Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. The Lancet. 2002. 360(9346): 1623-1630. doi: 10.1016/s0140-6736(02)11600-x

Deedwania P., Stone P.H., Bairey Merz C.N., et al. Effects of Intensive Versus Moderate Lipid-Lowering Therapy on Myocardial Ischemia in Older Patients With Coronary Heart Disease. Circulation. 2007. 115(6): 700-707. doi: 10.1161/circulationaha.106.654756

Miettinen T.A., Pyorä lä K., Olsson A.G., et al. Cholesterol-Lowering ̈ Therapy in Women and Elderly Patients With Myocardial Infarction or Angina Pectoris. Circulation. 1997. 96(12): 4211-4218. doi: 10.1161/01.cir.96.12.4211

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. The Lancet. 2002. 360(9326): 7-22. doi: 10.1016/s0140-6736(02)09327-3

Baigent C., Landray M.J., Reith C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011. 377(9784): 2181-2192. doi: 10.1016/S0140-6736(11)60739-3

Tonelli M., Wanner C. Lipid Management in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2013 Clinical Practice Guideline. Ann Intern Med. 2014. 160(3): 182-189. doi: 10.7326/m13-2453

Naci H., Brugts J., Ades T. Comparative Tolerability and Harms of Individual Statins. Circulation: Cardiovascular Quality and Outcomes. 2013. 6(4): 390-399. doi: 10.1161/circoutcomes.111.000071

Bruckert E., Hayem G., Dejager S., et al. Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO Study. Cardiovascular Drugs and Therapy. 2005. 19(6): 403-414. doi: 10.1007/s10557-005-5686-z

Davidson M.H., Clark J.A., Glass L.M., et al. Statin Safety: An Appraisal from the Adverse Event Reporting System. Am J Cardiol. 2006. 97(8): S32-S43. doi: 10.1016/j.amjcard.2005.12.008

Marcum Z.A., Vande Griend J.P., Linnebur S.A. FDA drug safety communications: a narrative review and clinical considerations for older adults. Am J Geriatr Pharmacother. 2012. 10(4): 264-271. doi: 10.1016/j.amjopharm.2012.05.002

Chalasani N., Aljadhey H., Kesterson J., et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004. 126(5): 1287-1292. doi: 10.1053/j.gastro.2004.02.015

Vuppalanchi R., Chalasani N., Teal E. Patients with Elevated Baseline Liver Enzymes Do Not Have Higher Frequency of Hepatotoxicity from Lovastatin than Those with Normal Baseline Liver Enzymes. Am J Med Sci. 2005. 329(2): 62-65. doi: 10.1097/00000441-200502000-00002

Dongiovanni P., Petta S., Mannisto V., et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol. 2015. 63(3): 705-712. doi: 10.1016/j.jhep.2015.05.006

Law M., Rudnicka A.R. Statin safety: a systematic review. Am J Cardiol. 2006. 97(8A): 52C-60C. doi: 10.1016/j.amjcard.2005.12.010

Li Y.H., Ueng K.C., Jeng J.S., et al. 2017 Taiwan lipid guidelines for high risk patients. J Formos Med Assoc. 2017. 116(4): 217-248. doi: 10.1016/j.jfma.2016.11.013

The authors declare that there are no conflicts of interest present.